Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3209-3214

  Zhu, Zhenping ^a   Rockwell, Patricia ^a,b   Lu, Dan ^a   Kotanides, Helen ^a   Pytowski, Bronislaw ^a   Hicklin, Daniel J ^a   Bohlen, Peter ^a   Witte, Larry ^a  

^a ELI LILLY AND COMPANY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR;

ANGIOGENESIS; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNOLOGY; CANCER INVASION; CONTROLLED STUDY; DNA SYNTHESIS; ENDOTHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; TUMOR GROWTH;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; BACTERIOPHAGES; CELLS, CULTURED; DNA; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032145315     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med., 1: 27-31, 1995.
2. Weinstat-Saslow, D., and Steeg, P. S. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J., 8: 401-407, 1994.
3. Liotta, L. A., Steep, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of negative and positive regulation. Cell, 64: 327-336, 1991.
4. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
5. Klagsbrun, M., and D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol., 53: 217-239, 1991.
6. Ferrara, N. Vascular endothelial growth factor. Trends Cardiovasc. Med., 3: 244-250, 1993.
7. Brown, L. F., Detmar, M., Claffey, K., Nagy, J. A., Feng, D., Dvorak, A. M., and Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In: I. D. Goldberg and E. M. Rosen (eds.), Regulation of Angiogenesis, pp. 233-269. Basel: Birkhauser Verlag, 1997.
8. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.
9. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N. P. H., Risau, W., and Ullrich, A. High-affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72: 835-846, 1993.
10. Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N., and Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. USA, 90: 7533-7537, 1993.
11. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res., 53: 5822-5827, 1993.
12. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
13. Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimtrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase receptor as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1992.
14. Kim, J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillip, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 362: 841-844, 1993.
15. Rockwell, P., and Goldstein, N. Role of protein tyrosine kinase receptors in cancer: possibilities for therapeutic intervention. Mol. Cell. Differ., 3: 315-335, 1995.
16. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusening, N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med., 3: 1222-1227, 1997.
17. Saleh, M., Stacker, S. A., and Wilks, A. F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res., 56: 393-401, 1996.
18. Ramakrishnan, S., Olson, T. A., Bautch, V. L., and Mohanraj, D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56: 1324-1330, 1996.
19. Rockwell, P., Neufeld, G., Glassman, A., Caron, D., and Goldstein, N. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Mol. Cell. Differ., 3: 91-109, 1995.
20. Tessler S., Rockwell, P., Hicklin, D., Cohen, T., Levi, B. Z., Witte, L., Lemischka, I. R., and Neufeld, G. Heparin modulates the interaction of VEGF165 with soluble and cell associated Flk-1 receptor. J. Biol. Chem., 269: 12456-12461, 1994.
21. Flanagan, J. G., and Leder, P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell, 63: 185-194, 1990.
22. D'angelo, G., Struman, I., Martial, J., and Weiner, R. I. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA, 92: 6374-6378, 1995.
23. Fan, T-P. D., Jaggar, R., and Bicknell, R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci., 16: 57-66, 1995.
24. Vukanovic, J., Passantii, A., Hirata, T., Traystman, R. J., Hartley-Asp, B and Isaacs, J. T. Antiangiogenesis effects of the quinoline-3-carboxamide linomide. Cancer Res., 53: 1833-1837, 1994.
25. Yamamoto, T., Sudo, K., and Fujita, T. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). Anticancer Res., 14: 1-4, 1994.
26. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 91: 4082-4085, 1994.
27. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K. P., and Shawver, L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
28. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
29. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
30. Van Meir, E. G., Polverini, P. J., Chazin, V. R., Huang, H-J. S., de Tribolet, N., and Cavenee, W. K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet., 8: 171-176, 1994.
31. Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A. Integral αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994.
32. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., and Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (Washington DC), 275: 547-550, 1997.
33. Pierce, E. A., Avery, R. L., Foley, E. D., Aiello, L. P., and Smith, L. E. H. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA, 92: 905-909, 1995.
34. Detmar, M., Brown, L. F., Claffey, K. P., Yeo, K-T., Kocher, O., Jackman, R. W., Berse, B., and Dvorak, H. F. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med., 180: 1141-1146, 1994.
35. Wizigmann-Voos, S., Bieier, G., Risau, W., and Plate, K. H. Up-regulation of vascular endothelial growth factor and its receptor in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res., 55: 1358-1304, 1995.
36. Koch, A. E., Harlow, L. A., Haines, G. K., Amento, E. P., Unemori, E. N., Wong, W. L., Pope, R. M., and Ferrara, N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol., 152: 4149-4156, 1994.
37. Albini, A., Soldi, R., Giunciuglio, D., Giraudo, E., Benelli, R., Primo, L., Noonan, D., Salio, M., Camussi, G., Rockl, W., and Bussolino, F. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on endothelial cells. Nat. Med., 2: 1371-1375, 1996.
38. Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., and Bohlen, P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk-1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev., in press, 1998.
39. Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., and Foeller, C. Sequences of Proteins of Immunological Interest, Ed. 5. Bethesda, MD: NIH, 1991.